Barclays Maintains Buy Rating for PTC with $233 Price Target

PTC (NASDAQ: PTC) received a new Buy recommendation from Barclays' Saket Kalia, with a price target of $233.00. The company's shares closed at $202.51. Kalia has a 5-star rating with an average return of 17.1% and a 64.62% success rate. PTC also received a Buy from KeyBanc's Jason Celino, but a Hold rating from Citi. The company has a one-year high of $213.14 and a one-year low of $133.38, with an average volume of 1.08M.

PTC Therapeutics (NASDAQ: PTC) has received a new Buy recommendation from Barclays' Saket Kalia, with a price target of $233.00. The company's shares closed at $202.51 on July 2, 2025. Kalia, who has a 5-star rating with an average return of 17.1% and a 64.62% success rate, has raised the target price from $46.00 to $233.00, indicating significant optimism in the company's future prospects [1].

The new recommendation comes as PTC Therapeutics continues to show strong performance, with a one-year high of $213.14 and a one-year low of $133.38. The company has also seen increased institutional trading, with several investors and hedge funds raising their stakes in the stock [1].

In addition to Barclays, KeyBanc's Jason Celino has also issued a Buy rating for PTC Therapeutics, while Citi has given a Hold rating. The company's average trading volume is 1.08 million shares, reflecting its growing popularity among investors [1].

On the earnings front, PTC Therapeutics reported strong results for Q3 2025, with constant currency ARR growth of 9.3% and free cash flow growth of 14% year-over-year. The company's CEO, Neil Barua, highlighted the importance of AI-driven digital transformation and the deepening partnership with NVIDIA [2].

Overall, the new Buy recommendations from Barclays and KeyBanc, along with the company's strong earnings performance, suggest that PTC Therapeutics is well-positioned for continued growth. However, investors should also consider the company's debt levels and the potential impact of policy and trade uncertainty on its deal pacing.

References:
[1] https://www.marketbeat.com/instant-alerts/barclays-forecasts-strong-price-appreciation-for-ptc-therapeutics-nasdaqptct-stock-2025-07-29/
[2] https://seekingalpha.com/news/4475067-ptc-signals-8-percent-to-9-percent-arr-growth-guidance-for-q4-while-emphasizing-ai-and-go-to